ADA: Lixisenatide Safe but Not Better for Heart (CME/CE)
MedPage Today,
(MedPage Today) -- ELIXA CV safety trial fails on superiority but does reassure on lack of risk
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
Overview of attention for article published in American Heart Journal, February 2015
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (94th percentile)
-
High Attention Score compared to outputs of the same age and source (86th percentile)
Mentioned by
- news
- 1 news outlet
- policy
- 1 policy source
- 6 X users
- patent
- 13 patents
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 266 Mendeley